This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Seropositive rheumatoid arthritis
DOID EFO MESH SNOMED Endpoint Browser
RHEUMA_SEROPOS
rheumatoid arthritis: A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters None
0 out of 7 registries used, show all original rules.
0
Check minimum number of events None
0
Remove individuals based on genotype QC
9984
RHEUMA_SEROPOS
Control definitions
Control exclude
RHEUMA_ENDPOINTS
Extra metadata
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Seropositive rheumatoid arthritis
based on the number of shared cases.
Broader endpoints:
- Polyarthropathies
- Finngen Rheumatological endpoints
- Arthropathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 9984 | 6826 | 3158 |
| Unadjusted prevalence (%) | 2.42 | 2.96 | 1.74 |
| Mean age at first event (years) | 54.23 | 52.42 | 58.15 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: RHEUMA_SEROPOS – Seropositive rheumatoid arthritis
GWS hits:
Survival analyses between endpoints
↥Plot
before Seropositive rheumatoid arthritis
after Seropositive rheumatoid arthritis
Loading survival analyses plot
Table
Loading survival analyses table
Drugs most likely to be purchased after Seropositive rheumatoid arthritis
↥Endpoint not on priority list, no data to show.